<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969367</url>
  </required_header>
  <id_info>
    <org_study_id>21D.214</org_study_id>
    <nct_id>NCT04969367</nct_id>
  </id_info>
  <brief_title>Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Measuring Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses feasibility and patient acceptability of using a Fitbit to monitor step&#xD;
      count and heart rate in transfusion dependent patients with myelodysplastic syndrome.&#xD;
      Information from this study may help researchers understand if there is any correlation&#xD;
      between activity level and anemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accrual rate</measure>
    <time_frame>Up to 90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Usage of the Fitbit device for at least 80% of the 90 days under observation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention Rate</measure>
    <time_frame>Up to 90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Will be measured by a short survey and interview addressing participant satisfaction.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Observational (activity monitor)</arm_group_label>
    <description>Patients wear an activity monitor (Fitbit) for 90 days. Patients also undergo collection of blood samples and complete questionnaires twice weekly for up to 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Device Usage and Evaluation</intervention_name>
    <description>Wear activity monitor (Fitbit)</description>
    <arm_group_label>Observational (activity monitor)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Observational (activity monitor)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (activity monitor)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (activity monitor)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with myelodysplastic syndrome (MDS) recruited from the Department of Medical&#xD;
        Oncology- Jefferson Health&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed pathologic diagnosis of MDS&#xD;
&#xD;
          -  Requiring &gt;= 2 blood transfusions in the past month if previously diagnosed or&#xD;
             hemoglobin =&lt; 8 g/dL if newly diagnosed&#xD;
&#xD;
          -  Age &gt;= 18&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          -  Ambulatory (use of a walking aid, such as a cane or rollator, is acceptable)&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Willing to comply with all study procedures and available for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Able to read and/or understand English&#xD;
&#xD;
          -  Have access to an iPhone 4S or later, iPad 3 generation or later, Android 5.0 or&#xD;
             later, or Windows 10 device&#xD;
&#xD;
          -  Have access to Bluetooth low energy (LE) and internet connection for syncing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Uncontrolled illness including, but not limited to, symptomatic congestive heart failure,&#xD;
        unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that&#xD;
        would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Wilde, MD</last_name>
      <phone>215-955-8874</phone>
      <email>Lindsay.Wilde@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

